Insight Molecular Diagnostics Inc.
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $4.1M
- Net income
- -$50.2M
- Total assets
- $25.8M
- Market cap
- $169.2M
- Gross margin
- 56.7%
- Operating margin
- -1260.8%
- Net margin
- -1238.5%
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $4.1M
- Cost of revenue
- $1.8M
- Gross profit
- $2.3M
- Operating expenses
- $53.4M
- Operating income
- -$51.1M
- Income tax
- $0
- Net income
- -$50.2M
- EPS (basic)
- $-1.65
- EPS (diluted)
- $-1.65
Balance sheet
- Total assets
- $25.8M
- Current assets
- $15.3M
- Total liabilities
- $57.2M
- Current liabilities
- $12.1M
- Shareholders’ equity
- -$31.5M
Cash flow
- Operating cash flow
- -$22.2M
- Investing cash flow
- -$3.2M
- Financing cash flow
- $28.1M
- Net cash flow
- $2.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $169.2M
- EPS (diluted)
- $-1.65
- Shares outstanding
- 29.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 30, 2015
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $50.2M in FY2025.
- Gross margin of 56.7%, net margin -1238.5%.
- Trading 33% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Insight Molecular Diagnostics Inc..
